Earnings Estimate Revisions for MAIA Biotechnology, Inc. This company is expected to earn -$0.75 per share for the fiscal year ending December 2025, which represents no year-over-year change ...

“MAIA continues to bring innovation to the biotech industry as one of the earliest pioneers of telomere targeting as a strategy for cancer treatment. Our lead candidate is THIO (ateganosine ...

In this article, we are going to take a look at where MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) stands against other cheapest stocks insiders are buying in March. After solid gains Monday ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...

MAIA’s letter to shareholders is available at ir.maiabiotech.com. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and ...

Investors might want to bet on MAIA Biotechnology, Inc. (MAIA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...